Clinical trial
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
NCT00310232 · Ontario Clinical Oncology Group (OCOG), Other · Terminated
Key facts
| NCT number | NCT00310232 |
|---|---|
| Title | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) |
| Official title | Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma, Lung Cancer, Anemia |
| Intervention type | Drug |
| Interventions | Epoetin Alfa |
| Enrollment | 70 |
| Start date | Feb 1, 2001 |
| Completion | Apr 1, 2004 |
| First posted | Apr 3, 2006 |
| Last update posted | Apr 2, 2024 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: